OBIO CAAP Company: ImmunoBiochem Wins at RESI San Francisco Innovation Challenge

Ontario Industry Updates
Written By Guest User

ImmunoBiochem, an OBIO CAAP company solving the problem of tumor heterogeneity won 2nd place at the highly competitive RESI San Francisco Innovation Challenge last week, during the JP Morgan Investor Conference.

Read the press release on their site

Guest User
Previous

VBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical Study of VBI-1901
Next

OBIO CAAP Company: ImmunoBiochem Wins at RESI San Francisco